Paul S. Mischel, M.D.
- B.A. - University of Pennsylvania
- M.D. - Cornell University Medical College
- Residency Training: UCLA, Dept of Pathology and Laboratory Medicine
- Postdoctoral Fellow: UCLA School of Medicine/ UCSF School of Medicine, Laboratory of Dr. Louis R. Reichardt, Howard Hughes Medical Institute
The Laboratory, headed by Dr. Paul Mischel, aims to transform the care of patients with glioblastoma, the most common form of brain cancer in adults, through molecular medicine. We use quantitative molecular approaches to study and understand the signaling networks that are altered in cancer cells in culture, in relevant in vivo cancer model systems and most importantly in human cancer patients. We have developed, and continue to develop, a suite of approaches for studying glioblastoma patients in state-of-the-art, moleculary guided clinical trials, with the goal of using this information to develop more effective, less toxic therapies. Our laboratory is patient-focused and greatly values interdisciplinary collaboration.
1) Signal Transduction in glioblastoma.
In cancer, response to targeted inhibitors is determined not only be the presence of the key mutant targets, but also by other critical changes in the molecular circuitry of cancer cells; e.g. such as loss of key tumor suppressor proteins, the selection for kinase resistant mutants and the deregulation of feedback loops. Our laboratory aims to elucidate this circuitry to develop more effective treatment strategies. We have a particular interest in the EGFR/PI3K/Akt/mTOR signaling network. The Mischel laboratory works very closely with Dr. Timothy Cloughesy and with several research laboratories across the US and internationally.
2) Studying the impact of molecularly targeted agents in patients.
Traditional pathologic methods are not sufficient for guiding molecularly targeted therapies. Our lab aims to develop quantitative molecular diagnostic tools to guide more effective, personalized cancer treatment. This includes new approaches for measuring signaling networks in complex heterogeneous tumor microvenvironments, including in cancer stem cells. This work leverages new nanotechnologies and physical science approaches developed in collaboration with the Heath laboratory at CalTech through the CalTech/UCLA/Institute of Systems Biology NanoSystems Biology Cancer Center.
3) Oncogenic signaling and altered cellular metabolism.
Understanding how oncogenic signaling in cancer regulates tumor cell metabolism and developing more effective strategies for targeting it.
Click here to visit Dr. Mischel’s Ludwig Institute laboratory website.
Dr. Paul Mischel heads the San Diego Branch's Laboratory of Molecular Pathology and also holds a professorship in the UCSD Department of Pathology. Dr. Mischel graduated Alpha Omega Alpha with an M.D. from Cornell University Medical College and trained in Anatomic Pathology and Neuropathology at UCLA. Dr. Mischel obtained his post-doctoral research training in the laboratory of Dr. Louis F. Reichardt at the Howard Hughes Medical Institute at UCSF and joined the UCLA faculty in 1998. Dr. Mischel has received a number of awards, including the Farber Award in 2007, the top brain tumor research award given jointly by the Society for Neuro-oncology and the American Association of Neurosurgery. Dr. Mischel's work was profiled by the Journal of Cell Biology in June 2008. Dr. Mischel was inducted into the American Society for Clinical Investigation (ASCI) in 2007 and was elected to serve on their council. He is the past President (2010-2011) of the ASCI.
Section 'Sub' Navigation:
Page 'Breadcrumb' Navigation: